Trials / Completed
CompletedNCT00512876
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Walter Reed Army Medical Center · Federal
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Accepted
Summary
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab (Avastin) | Bevacizumab 10mg/mL 1 drop BID x 3 weeks |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2007-08-08
- Last updated
- 2013-07-22
- Results posted
- 2013-07-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00512876. Inclusion in this directory is not an endorsement.